期刊
IMMUNOTARGETS AND THERAPY
卷 7, 期 -, 页码 35-49出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/ITT.S134842
关键词
cancer; melanoma; therapy; targets
类别
资金
- Portuguese Foundation for Science and Technology through a Post-Doc [SFRH/BPD/85249/2012]
- FCT
- FEDER - Fundo Europeu de Desenvolvimento Regional funds through COMPETE - Operational Programme for Competitiveness and Internationalisation (POCI), Portugal
- Portuguese funds through FCT - Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Inovacao [POCI-01-0145-FEDER-007274]
- Norte - Programa Operacional Regional do Norte
- European Regional Development Fund (ERDF) through the Operational Programme for Competitiveness and Internationalisation - COMPETE
- Portuguese national funds via FCT - Fundacao para a Ciencia e a Tecnologia [POCI-01-0145-FEDER-016390]
- [NORTE-01-0145-FEDER-000029]
Melanoma represents the most aggressive and the deadliest form of skin cancer. Current therapeutic approaches include surgical resection, chemotherapy, photodynamic therapy, immunotherapy, biochemotherapy, and targeted therapy. The therapeutic strategy can include single agents or combined therapies, depending on the patient's health, stage, and location of the tumor. The efficiency of these treatments can be decreased due to the development of diverse resistance mechanisms. New therapeutic targets have emerged from studies of the genetic profile of melanocytes and from the identification of molecular factors involved in the pathogenesis of the malignant transformation. In this review, we aim to survey therapies approved and under evaluation for melanoma treatment and relevant research on the molecular mechanisms underlying melanomagenesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据